Pegvisomant Side Effects: Safety Signals and Warnings
Pegvisomant safety concerns are compound-specific. The main listed side effects are Injection site reactions, Liver enzyme elevations (ALT, AST), and Headache. The main warning signals are Liver function tests must be monitored - cases of hepatitis and liver failure reported, Contraindicated in patients with hypersensitivity to pegvisomant or any excipient, and GH-secreting pituitary tumors may expand during treatment (loss of IGF-1 feedback) - monitor with MRI.
Direct Answer
Pegvisomant (Somavert) is FDA-approved for acromegaly and is the most effective agent for normalizing IGF-1 in GH-excess states - achieving normal IGF-1 in approximately 97% of patients in clinical practice. As a GH receptor antagonist rather than a somatostatin analog, its mechanism is fully distinct. For research into GH receptor physiology and GH excess disorders, pegvisomant is the pharmacological gold standard.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- Acromegaly treatment, GH receptor antagonism research, IGF-1 normalization
Reported Side Effects
- Injection site reactions
- Liver enzyme elevations (ALT, AST)
- Headache
- Nausea
- Diarrhea
- Flu-like symptoms
- Lipodystrophy at injection sites
Warnings
- Liver function tests must be monitored - cases of hepatitis and liver failure reported
- Contraindicated in patients with hypersensitivity to pegvisomant or any excipient
- GH-secreting pituitary tumors may expand during treatment (loss of IGF-1 feedback) - monitor with MRI
- Patients on insulin or oral hypoglycemics may need dose reduction due to improved glucose metabolism
- Do not use to treat conditions associated with GH deficiency
Known or Plausible Interactions
- Insulin and oral hypoglycemics (improved insulin sensitivity may cause hypoglycemia - reduce doses)
- Opioids (may increase GH levels, potentially requiring pegvisomant dose adjustment)
- Somatostatin analogs (may be used in combination but can reduce pegvisomant absorption)
Regulatory Context
FDA approved (2003, Somavert). Prescription required. Not a controlled substance.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | IGF-1 Normalization (Level A), Acromegaly Symptom Improvement (Level A), and Glucose Metabolism (Level B) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Pegvisomant Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/pegvisomant-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.